Biostream
At-home urine test plus AI to monitor neurological biomarkers and alert clinicians.
Company Overview
Snapshot
Founded in April 2025, Biostream operates with 1–10 employees. The company secured a Pre-Seed round in August 2025 led by ICI Fund.
Business overview
Biostream is developing a non-invasive, at-home urine testing system that leverages nano-sensors and artificial intelligence to detect and monitor neurological biomarkers. Its core product integrates a lateral flow assay (test strip) with smartphone scanning capabilities, securely transmitting results to a clinician-facing dashboard. This system aims to provide ongoing monitoring and facilitate earlier intervention for conditions such as hydrocephalus and normal pressure hydrocephalus (NPH), serving the health tech and life sciences sector, specifically within digital healthcare and patient remote monitoring.
Log in to access full profile ›Company Intelligence Q&A
- What is Biostream's primary focus?
- Biostream focuses on developing an at-home urine testing system that utilizes nano-sensors and AI to monitor neurological biomarkers, aiming to support ongoing monitoring and earlier intervention for conditions like hydrocephalus.
- When was Biostream founded?
- Biostream was founded in April 2025.
- Has Biostream received any non-equity funding?
- In November 2025, Biostream secured a grant from the Israel Innovation Authority.
- Which markets does Biostream serve?
- Biostream operates within the health tech and life sciences sector, specifically targeting digital healthcare and patient remote monitoring markets with its B2B and B2C business models.